Skip to content

Released Aug 11, 2022, before the open

10-Q filed Aug 11, 2022, 42 days after period end · 0001785530-22-000031

Q2 2022 · 10-Q
Revenue—
Net Income-$14.59MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.53N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$14,972,000N/M
Operating Cash Flowderived-$303,000N/M
Free Cash Flowderived-$1,414,000N/M

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020
Net Income-$14.59M-$10.92M$2.26M
EPS Diluted-$0.53-$3.82$0.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR